|drug1540||Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets Wiki||1.00|
|drug1539||Hydroxychloroquine Sulfate Tablets Wiki||0.71|
|D012141||Respiratory Tract Infections NIH||0.17|
|D014777||Virus Diseases NIH||0.10|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients with moderate and / or severe cases of this disease. Hydroxychloroquine and lopinavir / ritonavir have been shown to inhibit SARS-CoV viral replication in experimental severe acute respiratory symptoms models and have similar activity against SARS-CoV2. Although widely used in studies of critically ill patients, to date, no study has demonstrated its role on the treatment of high-risk, newly diagnosed patients with COVID-19 and mild symptoms.
Description: Hospitalization is defined as at least 24 hours of acute care in a hospital or similar acute care facility (emergency settings, temporary emergency facilities created for acute care of COVID-19 pandemic)Measure: Proportion of participants who were hospitalized for progression of COVID-19 disease Time: Measuring during 28-day period since randomization (Intention to treat analysis)
Description: Viral load change on 03, 07, 10 and 14 after randomization (200 patients per arm)Measure: Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization Time: Measuring during 14-day period since randomization
Description: Proportion of participants with clinical improvement, defined as normalization of temperature, Respiratory rate, SaO2, and cough relief (> 50% compared to baseline measured on a visual analog scale) in the last 72 hours.Measure: Time to clinical improvement Time: Measuring during 28-day period since randomization
Description: Proportion of participants with clinical improvement, defined as as time to need for hospitalization due to dyspnea, death, need for mechanical ventilation, shock and need for vasoactive amines;Measure: Time to clinical failure Time: Measuring during 28-day period since randomization
Description: Proportion of participants with hospitalization for any causeMeasure: Hospitalization for any cause Time: Measuring during 28-day period since randomization
Description: Evaluation of adverse events evaluated as associated to any of study armsMeasure: Proportion of participants who presented with adverse events Time: Measuring during 28-day period since randomization
Description: Proportion of participants who presented sustained improvement on respiratory scale defined as at least 48 hours of improvement.Measure: Time to improvement on respiratory scale symptoms Time: Measuring during 28-day period since randomization
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports